Developer docs
API playgroundTry for free, no card

Search company profiles

Exigent Research

Full company profile

uuid00hgmz8

Namestring
Exigent Research
Legal namestring
Exigent Research
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Exigent Research is a US-based, privately held oncology research network founded through a partnership between the Quality Cancer Care Alliance (QCCA) and the National Cancer Care Alliance (NCCA). The company aggregates 26+ independent community oncology practices operating 185+ sites with 660+ providers serving 426,000+ unique patients annually, primarily as a centralized hub for clinical trial administration rather than as a direct care provider. Its core platform combines three service modules: centralized processes (master clinical trial agreements, regulatory submissions, budget and contract negotiation), access to Phase I-IV clinical trials including Accelerated Trials on Demand (ATOD) for just-in-time trial activation, and a proprietary EMR-agnostic data warehouse with automated feeds including NGS testing for feasibility queries, patient identification, and real-world data analysis.

The business model is two-sided. Independent oncology practices join the network to offload administrative burdens and gain access to cutting-edge trials they could not individually support. Pharmaceutical and biotech trial sponsors pay Exigent to access a national footprint of community oncology sites, accelerating trial activation and patient enrollment through a single central point of contact rather than negotiating site-by-site. Exigent's go-to-market is enterprise sales-led: direct recruitment of practices into the network and direct engagement with sponsors via MCTA structures. Pricing is not publicly disclosed and operates through negotiated master and individual agreements. AI tooling enters the workflow through a strategic partnership with Tempus (Patient Query), applied to patient screening rather than developed in-house.

The company is led by Sibel Blau, MD (President/CEO, affiliated with Northwest Medical Specialties) with leadership drawn from across member practices, reflecting the consortium structure. Operations are headquartered in Tacoma, Washington. No funding rounds, M&A activity, or revenue disclosures were found in the source data, and the company's footprint is currently domestic-only.

Short descriptiontext

Exigent Research is a US-based oncology research network aggregating 26+ independent community oncology practices across 185+ sites to provide centralized clinical trial management services for pharmaceutical and biotech sponsors serving community cancer patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTacoma, United States
HQ citystring
Tacoma
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology clinical research, clinical trial management, community oncology network, cancer research services, clinical trial site network
Industry3 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Oncology Clinical Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Trial Management Services
TypeProfessional Services
Description

Exigent provides centralized administrative services for clinical trials including regulatory submissions, contract and budget negotiations, and master clinical trial agreements at the network level. Revenue is generated through fees from pharmaceutical/biotech sponsors for facilitating trial activation and management.

exigentnetwork.com
2Trial Sponsorship Revenue
TypeSubscription Recurring
Description

The network enables access to cutting-edge Phase I-IV clinical trials and pragmatic trials. Exigent generates revenue through its relationships with trial sponsors who leverage the network for patient enrollment and site activation.

exigentnetwork.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Exigent Research operates as a next-generation site network connecting independent community oncology practices across the United States with cancer clinical trials sponsored by pharmaceutical and biotech companies. The organization provides centralized processes, structured trial access, and a proprietary, EMR-agnostic data warehouse with automated data sourcing tools that enable faster trial activation, accelerated enrollment, and near-real-time trial lifecycle updates.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Exigent Research operates as a network-based clinical research platform that connects independent community oncology practices to accelerate cancer research. The core offering combines the Exigent Research Network (a consortium of 185+ independent oncology sites serving 426,000+ patients annually) with three integrated service modules: Centralized Processes (administrative support, regulatory submissions, master agreements, budget/contract negotiation), Access to Trials (Phase I-IV trials including Accelerated Trials on Demand™ for just-in-time activation, pragmatic trials, and observational trials), and Proprietary Data Warehouse (EMR-agnostic data tools for patient matching, real-world evidence, and network-wide insights). The platform is formed from a partnership between Quality Cancer Care Alliance (QCCA) and National Cancer Care Alliance (NCCA).

Product and service2 records
1Exigent Research Site Network
2Proprietary EMR-Agnostic Data Warehouse
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Tempus
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exigent Research Network partners with Tempus to leverage their AI-powered patient screening tool Patient Query for clinical trials. This partnership enables accelerated Phase I oncology trial enrollment, with Tempus's AI scanning both structured and unstructured clinical data to identify eligible patients across Exigent's network of community oncology practices.

tempus.com
2Quality Cancer Care Alliance (QCCA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

QCCA is a founding partner in the formation of Exigent Research. This partnership established the network-based model for accelerating cancer research by combining QCCA's existing network of oncology practices with the National Cancer Care Alliance.

exigentnetwork.com
3National Cancer Care Alliance (NCCA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NCCA is a founding partner in the formation of Exigent Research. This partnership contributed to building the deep networks and experience that power Exigent's unique network-based model for clinical cancer research.

exigentnetwork.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Syapse partners with community health systems to integrate oncology real-world data into research and precision medicine workflows; overlapping community-oncology data ambition but with a narrower focus on data vs. Exigent's site operations.

2Sarah Cannon Research Institute
TypeDirect peer
Description

Sarah Cannon is HCA Healthcare's oncology-focused clinical trial site network operating across the U.S. with Phase I units and a national reach; directly comparable to Exigent as a community oncology site network serving pharma sponsors.

TypeDirect peer
Description

US Oncology Research, part of McKesson, runs one of the largest community oncology clinical research programs in the U.S., performing Phase I-IV oncology trials; directly comparable network model targeting the same pharma sponsor segment.

4Tempus AI
TypeOthers
Description

Tempus is a stated strategic AI/data partner of Exigent via the Patient Query patient-screening tool; not a direct competitor but a critical enabling technology vendor whose AI capabilities directly power Exigent's trial matching.

TypeBroad incumbent
Description

Fortrea (post-Labcorp spinoff) runs global clinical development services including oncology site work; broader therapeutic scope but overlapping services in clinical trial operations for sponsors.

TypeBroad incumbent
Description

ICON is a global CRO with site management and oncology trial capabilities; comparable in trial-activation and patient-recruitment services but operates at substantially larger scale across multiple therapeutic areas.

TypeDirect peer
Description

OneOncology is a national partnership of independent community oncology practices; it coordinates research, value-based care, and operational services for its member sites, closely paralleling Exigent's independent-practice network thesis.

TypeBroad incumbent
Description

IQVIA is a global CRO with a large oncology site network and data capabilities serving pharma sponsors; overlaps with Exigent in trial operations but at much greater scale and breadth beyond oncology.

TypeBroad incumbent
Description

Flatiron (a Roche subsidiary) provides oncology-specific real-world evidence and EHR-to-research data technology used by community oncology practices; adjacent to Exigent's data warehouse play and targets the same pharma RWE buyers.

TypeDirect peer
Description

NCORP is a federally funded national network of community-based oncology sites conducting NCI-sponsored trials; comparable in function and structure as a multi-site oncology trial network, though sponsor base is government rather than pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exigent Research

Oncology Clinical Research Servicesexigentnetwork.com

Exigent Research is a US-based oncology research network aggregating 26+ independent community oncology practices across 185+ sites to provide centralized clinical trial management services for pharmaceutical and biotech sponsors serving community cancer patients.

What Exigent Research does

Exigent Research is a US-based, privately held oncology research network founded through a partnership between the Quality Cancer Care Alliance (QCCA) and the National Cancer Care Alliance (NCCA). The company aggregates 26+ independent community oncology practices operating 185+ sites with 660+ providers serving 426,000+ unique patients annually, primarily as a centralized hub for clinical trial administration rather than as a direct care provider. Its core platform combines three service modules: centralized processes (master clinical trial agreements, regulatory submissions, budget and contract negotiation), access to Phase I-IV clinical trials including Accelerated Trials on Demand (ATOD) for just-in-time trial activation, and a proprietary EMR-agnostic data warehouse with automated feeds including NGS testing for feasibility queries, patient identification, and real-world data analysis.

The business model is two-sided. Independent oncology practices join the network to offload administrative burdens and gain access to cutting-edge trials they could not individually support. Pharmaceutical and biotech trial sponsors pay Exigent to access a national footprint of community oncology sites, accelerating trial activation and patient enrollment through a single central point of contact rather than negotiating site-by-site. Exigent's go-to-market is enterprise sales-led: direct recruitment of practices into the network and direct engagement with sponsors via MCTA structures. Pricing is not publicly disclosed and operates through negotiated master and individual agreements. AI tooling enters the workflow through a strategic partnership with Tempus (Patient Query), applied to patient screening rather than developed in-house.

The company is led by Sibel Blau, MD (President/CEO, affiliated with Northwest Medical Specialties) with leadership drawn from across member practices, reflecting the consortium structure. Operations are headquartered in Tacoma, Washington. No funding rounds, M&A activity, or revenue disclosures were found in the source data, and the company's footprint is currently domestic-only.

Exigent Research firmographics

Firmographics
Name
Exigent Research
Legal name
Exigent Research
Website
https://exigentnetwork.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Exigent Research is a US-based oncology research network aggregating 26+ independent community oncology practices across 185+ sites to provide centralized clinical trial management services for pharmaceutical and biotech sponsors serving community cancer patients.
Ownership category
akta.pro rank

Exigent Research industry classification

Industry
Product category
Oncology Clinical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Oncology clinical research
  • Clinical trial management
  • Community oncology network
  • Cancer research services
  • Clinical trial site network

Where Exigent Research is headquartered

Location

Headquarters

HQ city
Tacoma
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Exigent Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Clinical Trial Management Services: Exigent provides centralized administrative services for clinical trials including regulatory submissions, contract and budget negotiations, and master clinical trial agreements at the network level. Revenue is generated through fees from pharmaceutical/biotech sponsors for facilitating trial activation and management.
  2. Trial Sponsorship Revenue: The network enables access to cutting-edge Phase I-IV clinical trials and pragmatic trials. Exigent generates revenue through its relationships with trial sponsors who leverage the network for patient enrollment and site activation.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Exigent Research product offering

Product offering

Core offering

Exigent Research operates as a next-generation site network connecting independent community oncology practices across the United States with cancer clinical trials sponsored by pharmaceutical and biotech companies. The organization provides centralized processes, structured trial access, and a proprietary, EMR-agnostic data warehouse with automated data sourcing tools that enable faster trial activation, accelerated enrollment, and near-real-time trial lifecycle updates.

Product overview

Exigent Research operates as a network-based clinical research platform that connects independent community oncology practices to accelerate cancer research. The core offering combines the Exigent Research Network (a consortium of 185+ independent oncology sites serving 426,000+ patients annually) with three integrated service modules: Centralized Processes (administrative support, regulatory submissions, master agreements, budget/contract negotiation), Access to Trials (Phase I-IV trials including Accelerated Trials on Demand™ for just-in-time activation, pragmatic trials, and observational trials), and Proprietary Data Warehouse (EMR-agnostic data tools for patient matching, real-world evidence, and network-wide insights). The platform is formed from a partnership between Quality Cancer Care Alliance (QCCA) and National Cancer Care Alliance (NCCA).

Differentiator

Problem solved

Functional benefit

Products and services

  • Exigent Research Site Network
  • Proprietary EMR-Agnostic Data Warehouse

Companies that use Exigent Research

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Exigent Research technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Exigent Research partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • TempuscoreStrategic or Co-development PartnerExigent Research Network partners with Tempus to leverage their AI-powered patient screening tool Patient Query for clinical trials. This partnership enables accelerated Phase I oncology trial enrollment, with Tempus's AI scanning both structured and unstructured clinical data to identify eligible patients across Exigent's network of community oncology practices.
  • Quality Cancer Care Alliance (QCCA)coreStrategic or Co-development PartnerQCCA is a founding partner in the formation of Exigent Research. This partnership established the network-based model for accelerating cancer research by combining QCCA's existing network of oncology practices with the National Cancer Care Alliance.
  • National Cancer Care Alliance (NCCA)coreStrategic or Co-development PartnerNCCA is a founding partner in the formation of Exigent Research. This partnership contributed to building the deep networks and experience that power Exigent's unique network-based model for clinical cancer research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Exigent Research competitors and assessment

Company assessment

Emerging players

  • Syapse: Syapse partners with community health systems to integrate oncology real-world data into research and precision medicine workflows; overlapping community-oncology data ambition but with a narrower focus on data vs. Exigent's site operations.

Direct peers

  • Sarah Cannon Research Institute: Sarah Cannon is HCA Healthcare's oncology-focused clinical trial site network operating across the U.S. with Phase I units and a national reach; directly comparable to Exigent as a community oncology site network serving pharma sponsors.
  • US Oncology Research: US Oncology Research, part of McKesson, runs one of the largest community oncology clinical research programs in the U.S., performing Phase I-IV oncology trials; directly comparable network model targeting the same pharma sponsor segment.
  • OneOncology: OneOncology is a national partnership of independent community oncology practices; it coordinates research, value-based care, and operational services for its member sites, closely paralleling Exigent's independent-practice network thesis.
  • National Cancer Institute (NCI) Community Oncology Research Program (NCORP): NCORP is a federally funded national network of community-based oncology sites conducting NCI-sponsored trials; comparable in function and structure as a multi-site oncology trial network, though sponsor base is government rather than pharma.

Others

  • Tempus AI: Tempus is a stated strategic AI/data partner of Exigent via the Patient Query patient-screening tool; not a direct competitor but a critical enabling technology vendor whose AI capabilities directly power Exigent's trial matching.

Broad incumbents

  • Labcorp Drug Development (now Fortrea): Fortrea (post-Labcorp spinoff) runs global clinical development services including oncology site work; broader therapeutic scope but overlapping services in clinical trial operations for sponsors.
  • ICON plc: ICON is a global CRO with site management and oncology trial capabilities; comparable in trial-activation and patient-recruitment services but operates at substantially larger scale across multiple therapeutic areas.
  • IQVIA Oncology: IQVIA is a global CRO with a large oncology site network and data capabilities serving pharma sponsors; overlaps with Exigent in trial operations but at much greater scale and breadth beyond oncology.
  • Flatiron Health: Flatiron (a Roche subsidiary) provides oncology-specific real-world evidence and EHR-to-research data technology used by community oncology practices; adjacent to Exigent's data warehouse play and targets the same pharma RWE buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Exigent Research social profiles

Digital presence

Exigent Research compliance and trust

Trust signal

Compliance2 records

Exigent Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exigent Research leadership team

Management profile

Number of profiles

Profiles8 records

Exigent Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exigent Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exigent Research

What does Exigent Research do?

Exigent Research operates as a next-generation site network connecting independent community oncology practices across the United States with cancer clinical trials sponsored by pharmaceutical and biotech companies. The organization provides centralized processes, structured trial access, and a proprietary, EMR-agnostic data warehouse with automated data sourcing tools that enable faster trial activation, accelerated enrollment, and near-real-time trial lifecycle updates.

Is Exigent Research a public or private company?

Exigent Research is a private company. It is classified as unknown and is currently operating.

When was Exigent Research founded?

Exigent Research was founded in -1. It employs 11 to 50 people.

Where is Exigent Research based?

Exigent Research is headquartered in Tacoma, United States, in the North America region.

How does Exigent Research make money?

Two revenue lines are on record. Clinical Trial Management Services are the primary driver. The others are trial Sponsorship Revenue.

Who are Exigent Research's main competitors?

Syapse is listed as an emerging player. Direct peers are Sarah Cannon Research Institute, US Oncology Research, OneOncology and National Cancer Institute (NCI) Community Oncology Research Program (NCORP). Tempus AI is listed as an others. Broad incumbents are Labcorp Drug Development (now Fortrea), ICON plc, IQVIA Oncology and Flatiron Health.

Does Exigent Research have an API?

No public API is recorded for Exigent Research.

What industry is Exigent Research in?

Exigent Research's product category is Oncology Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TempusImpact of AI on Clinical Trial Design and Patient Matching EfficiencyTempus deployed its AI-powered patient screening tool Patient Query across 8 clinical trials, achieving 94.39% accuracy and screening out approximately 72% of ineligible patients while increasing patients identified as potential matches by 27.31% following registered nurse review. The TIME Network, which spans 100 sites with over 1,500 active clinical trials, enables trial activation in as little as 10 days through its Just-in-Time model and has consented over 2,000 patients using generative AI to scan both structured and unstructured clinical data. Partnerships with companies including Pathos AI, Nimbus, and Exigent Research Network demonstrate how sponsors are leveraging Tempus's AI platform to accelerate Phase 1 oncology trial enrollment, with one study screening 244,986 patients across 16 sites.Business Wire BlogExigent Research, Leading National Community Research Network, Partners with AI Leader ConcertAI to Integrate CARAai™ Precision Trial SolutionsExigent Research and ConcertAI announced a multi-year partnership to integrate ConcertAI's CARAai™ precision trial solutions across Exigent's community oncology network. The suite will be tailored to all Exigent sites and EMRs, powered by NVIDIA NIM microservices and agentic AI. The partnership includes a roadmap for theranostics, CAR-T, and other novel therapies.Business Wire BlogExigent Research, Leading National Community Research Network, Partners with AI Leader ConcertAI to Integrate CARAai™ Precision Trial SolutionsExigent Research and ConcertAI announced a multi-year partnership to integrate ConcertAI's CARAai AI trial solutions across Exigent's community oncology network. The suite includes study feasibility, patient-to-trial matching, and AI-powered automations, with a roadmap for theranostics and CAR-T. Financial terms were not disclosed.Business Wire BlogExigent Research, Leading National Community Research Network, Partners with AI Leader ConcertAI to Integrate CARAai™ Precision Trial SolutionsExigent Research and ConcertAI announced a multi-year partnership to integrate ConcertAI's CARAai™ AI-powered trial solutions across Exigent's community oncology network. The suite includes study feasibility, patient-to-trial matching, and EMR integration, with a roadmap for theranostics and CAR-T. Financial terms were not disclosed.GlobeNewswireIndependent Oncology Networks Join Forces to Evolve Cancer Care by Launching Exigent ResearchNCCA and QCCA launched Exigent Research, a company of 25 independent oncology practices serving over 1.8 million patients. The entity centralizes services like contracting and IRB to expedite clinical trial access, reducing enrollment times. It plans to expand capabilities through industry partnerships.